Codeine

Active ingredient: Codeine Sulfate

In short: Codeine sulfate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. L i m i t ations of Use: Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any

Forms & strengthsEach 15 mg tablet for oral administration contains 15 mg of Codeine Sulfate, USP. It is a white, round, uncoated tablet, scored on one side, debossed “15” on the scored side and “LCI” on the other side. …
LabelLannett Company, Inc.
Label updatedFeb 05, 2026

What is Codeine used for?

Codeine sulfate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate.

L

i

m

i

t

ations of Use:

Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy , reserve opioid analgesics, including codeine sulfate tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

âš  Boxed warning (FDA's strongest warning)

Addiction, Abuse, and Misuse

Because the use of codeine sulfate tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions .

Life-Threatening

Respiratory

Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of codeine sulfate tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of codeine sulfate tablets are essential .

Accidental

Ingestion

Accidental ingestion of even one dose of codeine sulfate tablets, especially by children, can result in a fatal overdose of codeine .

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of codeine sulfate tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate .

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery . …

Codeine dosage

Codeine sulfate tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks.

Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals . Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of codeine sulfate tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.

Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available.

There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse .

Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with codeine sulfate tablets. Consider this risk when selecting an initial dose and when making dose adjustments .

Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). Discuss the importance of having access to an opioid overdose reversal agent, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose. The presence of risk factors for overdose should not prevent the management of pain in any patient .

Discuss the options for obtaining an opioid overdose reversal agent (e.g., prescription, over-the-counter, or as part of a community-based program) .

There are important differences among the opioid overdose reversal agents, such as route of administration, product strength, approved patient age range, and pharmacokinetics. Be familiar with these differences, as outlined in the approved labeling for those products, prior to recommending or prescribing such an agent.

Initiating Treatment with Codeine Sulfate Tablets:

Initiate treatment with codeine sulfate tablets in a dosing range of 15 to 60 mg every 4 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia. …

How to take Codeine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Storage and Disposal:

Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store codeine sulfate tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home. Inform patients that leaving codeine sulfate tablets unsecured can pose a deadly risk to others in the home .

Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Inform patients that medicine take-back options are the preferred way to safely dispose of most types of unneeded medicines. …

Warnings & precautions

Do not take this medicine if: Codeine sulfate tablets are contraindicated for:

All children younger than 12 years of age .

Post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy .

Codeine sulfate tablets are also contraindicated in patients with:

Significant respiratory depression .

Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment .

Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days .

Known or suspected gastrointestinal obstruction, including paralytic ileus .

Hypersensitivity to codeine (e.g., anaphylaxis) .

Codeine sulfate tablets contain codeine, a Schedule II controlled substance. As an opioid, codeine sulfate tablets exposes users to the risks of addiction, abuse, and misuse .

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed codeine sulfate tablets. Addiction can occur at recommended dosages and if the drug is misused or abused. The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy. In postmarketing studies, addiction, abuse, misuse, and fatal and non-fatal opioid overdose were observed in patients with long-term opioid use .

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing codeine sulfate tablets, and reassess all patients receiving codeine sulfate tablets for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. …

Codeine side effects

The following serious adverse reactions are described, or described in greater detail, in other sections:

Addiction, Abuse, and Misuse

Life-Threatening Respiratory Depression

Interactions with Benzodiazepines and Other CNS Depressants

Neonatal Opioid Withdrawal Syndrome

Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children

Opioid-Induced Hyperalgesia and Allodynia

Adrenal Insufficiency

Severe Hypotension

Gastrointestinal Adverse Reactions

Seizures

Withdrawal

The following adverse reactions associated with the use of codeine were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Serious adverse reactions associated with codeine were respiratory depression and, to a lesser degree, circulatory depression, respiratory arrest, shock, and cardiac arrest.

The most frequently observed adverse reactions with codeine administration included drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, sweating, and constipation.

Other adverse reactions included allergic reactions, euphoria, dysphoria, abdominal pain, and pruritis. …

Drug interactions

Table 1 includes clinically significant drug interactions with codeine sulfate tablets.

Inhibitors of CYP3A4

C

li

n

i

cal

Impact: | The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved .

After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels , resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to codeine.

Intervention: | If concomitant use of CYP3A4 inhibitor is necessary, consider dosage reduction of codeine sulfate tablets until stable drug effects are achieved. Evaluate patients at frequent intervals for respiratory depression and sedation.

If a CYP3A4 inhibitor is discontinued, consider increasing the codeine sulfate tablets dosage until stable drug effects are achieved. …

About this medicine

Codeine Sulfate Tablets, USP contain codeine, an opioid agonist, available for oral administration containing either 15 mg, 30 mg, or 60 mg of codeine sulfate, USP. The chemical name is morphinan-6-ol,7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-(5α,6α)-, sulfate (2:1) (salt), trihydrate. Its molecular formula is (C18H21NO3)2 • H2SO4 • 3H2O and its molecular weight is 750.85 g/mol.

Its structure is as follows:

Codeine sulfate trihydrate is a fine, white, crystalline powder which is soluble in water and insoluble in chloroform and ether.

The inactive ingredients in codeine sulfate tablets, USP include: microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, talc, and stearic acid.

How it works: Codeine sulfate is an opioid agonist relatively selective for the mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic properties of codeine have been speculated to come from its conversion to morphine, although the exact mechanism of analgesic action remains unknown. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5819bdf7-300e-45b8-8f3a-447b53656293. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine